title: Plasmid DNA and viral vector-based vaccines for the treatment of cancer.
abstract: Plasmid DNA and viral vector-based cancer vaccines have many inherent features that make them promising cancer vaccine candidates. This review focuses on the use of plasmid DNA and viral vector vaccines to deliver tumour-specific antigens to induce a tumour-specific immune response. Examples of different antigen delivery systems that have been tested in recent clinical trials are summarised and advantages and disadvantages of a number of delivery systems and approaches are discussed. Finally, an outlook on how plasmid DNA and viral vectors might be developed further as cancer vaccines is provided.
authors: Oxxon Therapeutics Ltd., 2nd Floor Florey House, 3 Robert Robinson Avenue, Oxford Science Park, Oxford OX4 4GP, UK.
authors: Richard J
authors: RJ
authors: Anderson
authors: Joerg
authors: J
authors: Schneider
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000379:methods*; D005822:Genetic Vectors / Q000276:immunology; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D010957:Plasmids / Q000235:genetics; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology; D014765:Viral Vaccines / Q000627:therapeutic use*
chemical_list: D019496:Cancer Vaccines; D019444:Vaccines, DNA; D014765:Viral Vaccines